Malacky

• A randomized, double-blind, placebo-controlled multicenter study to evaluate the effect of inclisiran on preventing major adverse cardiovasc … Unknown
  2022-502779-40-99 5 Primary prevention of atherosclerotic cardiovascular disease (ASCVD)
• PHARMACOKINETICS OF PETRELINTIDE FOLLOWING ADMINISTRATION TO PARTICIPANTS WITH IMPAIRED HEPATIC FUNCTION Recruiting
  2025-523641-10-00 3 2026-05-18 Healthy / hepatic impaired volunteers only study to assess PK paramete
• A research study looking into blood levels of the medicine NNC0487 0111 in the body and how well it is tolerated in people with reduced live … Recruiting
  2025-521647-20-00 3 2026-05-12 hepatic impairment
• A research study comparing how well different doses of the medicine NNC0662-0419 lower blood sugar in people with type 2 diabetes Recruiting
  2025-523260-20-00 4 2026-04-28 type 2 diabetes
• A Study to Evaluate the Effect of Obicetrapib and Ezetimibe Fixed-Dose Combination (FDC) or Obicetrapib on LDL-C in Participants With Type 2 … Recruiting
  2025-521936-12-00 5 2026-04-24 Adults with Type 2 Diabetes and/or Metabolic Syndrome on guideline re
• Evaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants with Atherosclerotic Cardiovascular Disease and … Recruiting
  2024-516652-18-00 5 2025-10-10 Atherosclerotic cardiovascular disease (ASCVD) and obesity or overweig
• A Trial to Test How AZD0780 Affects Serious Heart, Stroke, or Vascular Problems in Patients with Heart, Stroke or Vascular Disease or at Hig … Recruiting
  2025-520519-14-00 5 2025-09-03 Atherosclerotic Cardiovascular Disease
• 202301CPC Redefine-HF Recruiting
  2023-508581-15-00 5 2024-10-08 Heart condition
• A Study to Find Out How Safe and Well AZD0780 Works for Adults with High 'Bad' Cholesterol and with Heart- Stroke or Vascular Disease or at … Ended recruitment
  2025-520521-21-00 5 2025-09-02 Hyperlipidemia
• A randomized, double-blind, placebo-controlled multicenter study to evaluate the effect of inclisiran on preventing major adverse cardiovasc … Ended recruitment
  2022-502779-40-00 5 2023-09-04 Primary prevention of atherosclerotic cardiovascular disease (ASCVD)
• HERMES – A research study to look at how ziltivekimab works compared to placebo in people with heart failure and inflammation. Ended recruitment
  2022-501939-16-00 5 2023-05-09 Heart failure (HF) with mildly reduced ejection fraction (HFmrEF) or H
• A Study to Evaluate the Effects of Various Degrees of Hepatic Impairment on the Pharmacokinetics of A Single Subcutaneous Dose Of RO7434656, … Ended
  2023-508270-29-01 3 2024-09-24 Hepatic Impairment
• REIMAGINE 3: A research study to see how much CagriSema lowers blood sugar and body weight compared to placebo in people with type 2 diabete … Ended
  2022-502679-43-00 5 2024-04-12 Type 2 diabetes
• A Phase 3 study to assess efficacy and safety of oral tebipenem compared to IV imipenem-cilastatin in adults with cUTI/AP Ended
  2023-503785-22-00 5 2024-03-25 complicated urinary tract infection (cUTI) or acute pyelonephritis (AP
• A study to learn more about how well BAY 3018250 works and how safe it is for people with proximal deep vein thrombosis Ended
  2023-503315-15-00 4 2023-12-20 Thrombolysis of symptomatic proximal vein thrombosis
• REIMAGINE 2: A research study to see how well CagriSema compared to semaglutide, cagrilintide and placebo lowers blood sugar and body weight … Ended
  2022-502678-18-00 5 2023-11-07 Type 2 diabetes
• A Study About Fazirsiran in People With and Without Liver Problems. Ended
  2023-503735-17-00 3 2023-10-05 Hepatic impairment.
• A Study of Retatrutide (LY3437943) in Participants With Obesity and Cardiovascular Disease (TRIUMPH-3) Ended
  2023-503659-88-00 5 2023-09-05 Cardiovascular Disease
• A Double-Blind Placebo-Controlled Randomised Phase 1b Study of the Pharmacokinetics of ALE.F02 in Patients with Advanced Liver Fibrosis and/ … Ended
  2024-516455-40-00 3 2023-05-25 Advanced liver fibrosis and/or mild liver cirrhosis
• A study to test trimodulin in adult hospitalized patients with CAP including COVID-19 pneumonia. Ended
  2024-513002-60-00 5 2022-10-26 Non-severe community-acquired pneumonia (CAP) or moderate or severe Co

Showing 1–20 of 20 trials